| Previous Close | 86.14 |
| Open | 85.00 |
| Volume | 1,195,182 |
| Avg. Volume (3M) | 1,685,398 |
| Market Cap | 42,794,176,512 |
| Price / Earnings (TTM) | 38.45 |
| Price / Earnings (Forward) | 27.47 |
| Price / Sales | 4.32 |
| Price / Book | 1.94 |
| 52 Weeks Range | |
| Earnings Date | 19 Aug 2025 |
| TTM Dividend Yield | 0.36% |
| Profit Margin | 11.28% |
| Operating Margin (TTM) | 13.30% |
| Diluted EPS (TTM) | 2.25 |
| Quarterly Revenue Growth (YOY) | 0.60% |
| Quarterly Earnings Growth (YOY) | 41.10% |
| Total Debt/Equity (MRQ) | 23.63% |
| Current Ratio (MRQ) | 2.70 |
| Operating Cash Flow (TTM) | 2.12 B |
| Levered Free Cash Flow (TTM) | 1.18 B |
| Return on Assets (TTM) | 2.74% |
| Return on Equity (TTM) | 5.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Alcon Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 2.00 |
|
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Large Core |
| % Held by Insiders | 0.13% |
| % Held by Institutions | 67.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 120.00 (Mizuho, 38.70%) | Buy |
| Median | 112.00 (29.45%) | |
| Low | 110.00 (Needham, 27.14%) | Buy |
| Average | 114.00 (31.76%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 92.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 14 May 2025 | 110.00 (27.14%) | Buy | 87.24 |
| 28 Mar 2025 | 110.00 (27.14%) | Buy | 95.77 | |
| Keybanc | 31 Mar 2025 | 112.00 (29.45%) | Buy | 94.93 |
| Mizuho | 28 Mar 2025 | 120.00 (38.70%) | Buy | 95.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Jun 2025 | Announcement | Alcon Canada Earns Global Recognition as a Top Employer |
| 20 Jun 2025 | Announcement | Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL |
| 28 May 2025 | Announcement | Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease |
| 13 May 2025 | Announcement | Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS |
| 06 May 2025 | Announcement | Alcon Announces Results of 2025 Annual General Meeting |
| 25 Apr 2025 | Announcement | Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS |
| 02 Apr 2025 | Announcement | Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter |
| TTM Dividend Yield | 0.36% |
| 4Y Average Dividend Yield | 0.26% |
| Payout Ratio | 11.81% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 14 May 2024 | 08 Apr 2024 | 16 May 2024 | 0.2644 Cash |
| 10 May 2023 | 30 Mar 2023 | 12 May 2023 | 0.2356 Cash |
| 29 Apr 2022 | 24 Mar 2022 | 05 May 2022 | 0.2083 Cash |
| 04 May 2021 | 24 Mar 2021 | 06 May 2021 | 0.0909 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.264 | 1 | 0.31 |
| 2023 | 0.236 | 1 | 0.30 |
| 2022 | 0.208 | 1 | 0.30 |
| 2021 | 0.091 | 1 | 0.10 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |